On Tuesday, Moderna MRNA got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73. This exclusive rating ...

Moderna shares are volatile Monday after the company provided updates on its business and pipeline at a healthcare conference ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Elie Honig, a former federal and state prosecutor and CNN senior legal analyst, has closely followed the turmoil in Chicago ...